DXB Dimerix Limited
Healthcare · Biotechnology
· website
· 15 employees
$0.26
52wk 0.16 – 0.67
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Dimerix Limited
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$156.10M
P/E (trailing)
—
P/E (forward)
-13.00
EPS (trailing)
-0.03
Dividend yield
—
Payout ratio
0.0%
Beta
0.33
EV / EBITDA
-2.70
Price / Book
-86.67
ROE
-594.5%
Operating margin
-1,026.2%
Net margin
-219.9%
Total cash
$38.49M
Total debt
$33,418
Current ratio
3.15
Debt / Equity
—
Free cash flow
$-16.89M
Avg volume
2.53M
Latest annual results
(FY ending 30 Jun 2025)
- Revenue$5.59M
- Gross profit$5.59M
- Operating income-$32.01M
- Net income-$13.25M
- Diluted EPS-0.02
- Free cash flow$39.03M
- Net debt-$68.19M